Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Chronic Myeloid Leukemia News
CHRONIC MYELOID LEUKEMIA ADVISOR
Chronic Myeloid Leukemia News
Chronic Myeloid Leukemia: 5 Myths You May Encounter
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
Duration of TKI Treatment Predicts Early, Late Recurrence in Chronic Myeloid Leukemia
The underlying mechanisms of late recurrence must be investigated further, according to researchers.
Many Oncology Drugs Approved for Genomic Indications Not Studied for Overall Survival Outcomes
Overall survival data were available for about half of the drugs.
Asciminib Continues to Demonstrate Superior Efficacy vs Bosutinib in Chronic Phase Chronic Myeloid Leukemia
Updated data demonstrated asciminib significantly improved the rate of MMR at 48 weeks compared with bosutinib.
Seroconversion After COVID-19 Vaccination High in CML, Low in NHL
Seroconversion was observed in 99% of patients with chronic myeloid leukemia.
Ankle-Brachial Index, Cardiac Ankle Vascular Index May Indicate Risk of Cardiovascular AEs in Patients With CML Taking TKIs
A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
Factors That Impact HRQOL in Pediatric Patients With Chronic Myeloid Leukemia
Patients’ age, sex, and treatment-related symptoms, as well as mothers’ education level, were significantly associated with HRQOL.
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid Leukemia
Researchers sought to determine whether there was a difference in generic or branded imatinib in treating patients with CML.
Scemblix Approved for Ph+ Chronic Myeloid Leukemia in Chronic Phase
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
Algorithm Assesses Risk of Major Adverse Cardiovascular Events in TKI-Treated CML
Researchers sought to determine the accuracy of established tools in predicting the risk of cardiovascular events in patients with CML receiving TKIs.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Utilization Patterns Explain Nonadherence to Treatment for Multiple Myeloma, CML, Some Metastatic Cancers
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Optimal Starting Dose of Ponatinib for Chronic Phase Chronic Myeloid Leukemia
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Comorbidities Don’t Hinder Dasatinib’s Activity in Chronic Phase Chronic Myeloid Leukemia
Dasatinib produced responses regardless of comorbidity burden.
New-Generation BCR-ABL TKIs Linked to Increased Risk of Hepatotoxicity in Patients With Chronic Myeloid Leukemia
Researchers sought to determine the risk of hepatotoxicity for patients with CML treated with 4 newer TKIs compared with imitanib.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Registry Data Support Use of Ponatinib in CML, Ph+ ALL Resistant or Intolerant to Tyrosine Kinase Inhibitors
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...